APOE genotype and age modifies the correlation between cognitive status and metabolites from hippocampus by a 2D $^1$H-MRS in non-demented elders

Zhenyu Yin$^{1,*}$, Wenbo Wu$^2{,*}$, Renyuan Liu$^3$, Xue Liang$^4$, Tingting Yu$^1$, Xiaoling Chen$^1$, Jie Feng$^1$, Aibin Guo$^4$, Yu Xie$^1$, Haiyan Yang$^1$, Mingmin Huang$^4$, Chuanshuai Tian$^4$, Bing Zhang$^4$ and Yun Xu$^3$

$^1$ Department of Geriatrics, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
$^2$ Department of Neurology, Affiliated Drum Tower Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
$^3$ Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
$^4$ Department of Radiology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
$^*$ These authors contributed equally to this work.

ABSTRACT

Purpose. To examine the associations among age, Apolipoprotein E (APOE) genotype, metabolic changes in the hippocampus detected by 2D $^1$H magnetic resonance spectroscopy (MRS), and neuropsychological measures of cognition in non-demented elders.

Materials and Methods. We studied a cohort of 16 cognitively normal controls (CN) and 11 amnestic mild cognitive impairment (aMCI) patients between 66 and 88 years old who were genotyped for APOE genetic polymorphism. Measurements of 2D $^1$H-MRS metabolites were obtained in the hippocampus region. Adjusting by age among all subjects, the association between metabolic changes and cognitive function was measured by Spearman partial rank-order correlation. The effect of APOE status was measured by separating the subjects into APOE genotype subgroups, including the APOE$^{\varepsilon 4}$ carriers and APOE$^{\varepsilon 4}$ non-carriers.

Results. In contrast to the CN group matched with age, gender, and education, aMCI patients showed increased myo-inositol (mI)/Creatine (Cr) ratio only in the right hippocampus. No differences were noted on N-acetylaspartate (NAA)/Cr and mI/NAA from bilateral hippocampus, and so was mI/Cr ratio in left hippocampus between aMCI and CN. The mI/Cr ratio from the right hippocampus in non-demented elders was negatively correlated with Montreal Cognitive Assessment (MoCA) scores. Whether $\varepsilon 4$ genotype or age was added as a covariate, none of the correlation effects remained significant. Additionally, adjusting for age and APOE genotype together, there was no significant correlation between them.

Conclusion. Since the higher mI/Cr from the right hippocampus of the patients with aMCI than those from CN, the mI/Cr could be a more specific predictor of general cognitive function in aMCI patients. There is an association between higher mI/Cr in right hippocampus and worse cognitive function for the non-demented older adults,
and the correlation could be modified by APOE status and age. That provided a window on objectively understanding the mechanism between the brain metabolites and the influence factors in non-demented elders.

Subjects  Neuroscience, Diabetes and Endocrinology, Geriatrics, Metabolic Sciences
Keywords  Amnestic mild cognitive impairment, 2D\(^1\)H-MRS metabolites, Hippocampus, APOE genotype, Age

INTRODUCTION

The proton magnetic resonance spectroscopy (\(^1\)H MRS) is unique among diagnostic imaging modalities because the signals from several different metabolites are measured. It is a potential metabolic marker in Alzheimer’s disease (AD) for both early diagnoses and evaluating treatment effects (Graff-Radford & Kantarci, 2013; Murray et al., 2014; Tumati, Martens & Aleman, 2013). MRS allows regional measurement of metabolites including myo-inositol (mI), choline (Cho), N-acetyl aspartate (NAA), and creatine (Cr). Cr is typically used as an internal reference to control for variability in measurement because it remains unchanged in AD (Kantarci, 2007). The mI/Cr ratio is associated with glia and elevated levels with glial proliferation. Glial and microglial activity raises the possibility that elevated mI represents inflammation which is an early event in the evolution of AD pathology (Graff-Radford & Kantarci, 2013).

However, more and more evidences showed that despite of mI initially changed in early AD, mI/Cr was not related to the pathological severity of AD and could not predict the AD progression. For example, an autopsy study showed the subjects with a low likelihood of AD and sparse neuritic plaques had higher mI/Cr ratios than the subjects with an intermediate likelihood of AD and moderate neuritic plaques (Kantarci et al., 2008). A longitudinal study also found the annual percent change in mI/Cr ratios was not different between amnestic subtype of MCI (aMCI)-stable and aMCI-converter who progressed to AD during follow up (Kantarci et al., 2007). Furthermore, the mI levels were found to be associated with general cognition (such as MMSE, MoCA) in one study (Rose et al., 1999), but not associated with Mini-Mental State Examination (MMSE) in another study (Huang et al., 2001). Therefore, the association between metabolites and cognitive measures remains controversial.

There are some factors that potentially influence the cognitive impairment. Apolipoprotein E (APOE) genotype is the best established susceptibility gene and has been shown to influence age of onset (Mastaglia et al., 2013) and the underlying histopathology of AD (Michaelson, 2014). Carriers of the APOE\(^\varepsilon4\) allele have an increased risk of cognitive decline (Kozauer et al., 2008). Age is another main factor affecting cognitive function. A study using general linear model analysis demonstrated that older APOE\(^\varepsilon4\) carriers had significantly higher mI than APOE\(^\varepsilon3\) homozygotes in a healthy aging normal population (Gomar et al., 2014). But it has been previously suggested that the APOE effect dissipated for old individuals who were more than 80 year old (Negash et al., 2009).
To the best of our knowledge, there is still no evidence for the effect of APOE genotype and age on the relationship between metabolites and cognitive status in aMCI patients. Therefore, our primary objective was to determine the metabolic changes in the hippocampus measured by 2D $^1$H-MRS in aMCI patients compared with normal controls. We hypothesized that aMCI patients have increased mI/Cr ratio in the hippocampus compared with normal elderly. In addition, APOE genotype and age may impact the correlation between metabolites and cognitive status in aMCI patients. In this way, we might be able to elucidate the influence factors on the association between metabolites and cognitive measures.

**METHODS AND MATERIALS**

**Participants**

Participants were recruited at the Memory clinic of Neurology Department in Nanjing Drum Tower Hospital during a 19-month span from September 1, 2011 to April 31, 2013. The study was approved by the Medical Research Ethics Committee of Nanjing Drum Tower Hospital, Nanjing, China, and all the subjects’ written informed consents were obtained before the study. Participants were classified based on the clinical criteria and results of the neuropsychological tests into the aMCI and CN groups. Participants in aMCI group met the Petersen’s criteria (*Petersen, 2000*; *Petersen, 2004*), which included (a) memory complaint, preferably confirmed by an informant; (b) objective memory impairment, adjusted for age and education; (c) normal or near-normal performance on general cognitive functioning and no or minimum impairment of daily life activities; (d) the Clinical Dementia Rating (CDR) score of 0.5; and (e) not meeting the criteria for dementia according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4rd edition, revised). Patients with aMCI were diagnosed by experienced neurologists. Cognitive normal controls (CN) were identified as individuals who (a) had no cognitive complaints, (b) had a normal level of clinical rating scales, and (c) had no evidence of any abnormality examined by a conventional MRI.

Subjects were excluded if they met the following clinical characteristics: (a) those who have a clear history of stroke; (b) severe depression that led to aMCI (Hamilton Depression Rating Scale score ≥ 24 points); vascular dementia (Hachinski scores ≥ 7); (c) other nervous system diseases, which can cause cognitive impairment (such as brain tumors, Parkinson’s disease, encephalitis, and epilepsy); (d) cognitive impairment caused by traumatic brain injury; (e) other systemic diseases, which can cause cognitive impairment, such as thyroid dysfunction, severe anemia, syphilis, and HIV; and (f) a history of psychosis or congenital mental growth retardation.

**Cognitive assessment**

All of subjects were evaluated using a standardized clinical evaluation protocol, which included Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), Activity of Daily Living Scale (ADL), Hachinski Ischemic Scaling (HIS) and Hamilton Depression Scale (HAMD) to exclude...
vascular cognitive impairment and depression state. Memory and executive function was assessed through ADAS-cog test. Wechsler Adult Intelligence Scale including digital symbol and digital span were also tested for all participants.

**Genotyping**

Genotyping was conducted using Polymorphic DNA at two loci in APOE exon 4 by amplicon sequencing methods to produce small polymerase chain reaction products that serve as the templates for bidirectional sequencing. Participants with APOE genotype 2/2, 2/3 were labeled ε2 carriers, genotype 3/3 was labeled ε3 homozygote, genotypes 3/4 and 4/4 were labeled ε4 carriers.

**Proton magnetic resonance spectroscopy**

All MRI examinations were performed at 3 T using an 8-channel phased array head coil (Achieva 3.0T TX dual-source parallel RF excitation and transmission technology, Philips Medical Systems, The Netherlands).

A three-dimensional turbo fast echo (3D-TFE) $T_1$WI sequence on sagittal view with repetition time (TR)/echo time (TE) = 9.8/4.6 ms; flip angle = 8°; field of view (FOV) = 256 × 256 mm$^2$, and a slice thickness of 1 mm was performed for reformatting transverse images. Then, the transverse image of bilateral hippocampi as the main reference image was obtained by reformatting the 3D-TFE $T_1$WI image from Philips Achieva 3.0T MR Extended Workspace (EWS) for localizing the $^1$H-MRS sequence on hippocampus. A two-dimensional Point-resolved spectroscopy (2D-PRESS) pulse sequence with TR/TE = 2,000/32 ms, flip angle = 90°, FOV = 100 × 100 mm, acquisition voxel = 12 × 12 mm, reconstruction voxel = 4 × 4 mm and thickness = 8 mm was performed for each side of the hippocampus, respectively. The VOI (voxel of interest, 64 × 32 mm in this study) of 2D-PRESS was located on the transverse image of bilateral hippocampi, and its long axis is parallel with the hippocampus referenced by sagittal 3DT$T_1$W image, with the caution of avoiding the surrounding bone, air and fat. We selected the hippocampus voxel (18∼27) in the effective voxel based on the hippocampal anatomy actual form. A voxel was considered eligible whenever more than two-thirds of its area was located within hippocampus area. Finally, the average magnitude spectra per voxel were computed by summation of the voxel spectra from the defined volume of interest (VOI) and division by the number of voxels (Shen et al., 2009; Weis et al., 2014). The chemical shift distance was considered in the localization process by double-checking the chemical shift voxels of NAA and mI, respectively (Fig. 1). The MRS acquisition time was about 6 min and 6 s.

The MRS metabolite ratios were determined for NAA/Cr, mI/Cr and mI/NAA. Ratios were quantified automatically with Philips WorkStation software (Extended Workspace, EWS). The measured Cr peak includes both the metabolites Cr and phosphocreatine and is thought to be a reliable marker of brain energy metabolism, often used as a relatively stable reference level (Kantarci, 2007).
Statistical analyses

Statistical analysis was performed by software (SPSS version 16.0; SPSS, Chicago, Illinois) for demographic and clinical data. For our primary analysis, we summarize associations between cognition and $^1$H-MRS metabolite ratios using Spearman partial rank-order correlations which we denote by “partial $r_s$.” Due to the limitation of our sample size, we used partial $r_s$ to quantify associations since it is a nonparametric correlation between 2 variables which does not assume normally distributed data and therefore is preferable in this situation. Next, we report partial Spearman rank-order correlations adjusting for age, gender, and education among all subjects. The effect of APOE genotype on the association between cognitive function and $^1$H-MRS metabolite ratios was adjusted by APOE genotype subgroups. We separated the APOE$e4$ carriers ($e3e4$ and $e4e4$) and APOE$e4$ non-carriers ($e2e2$, $e2e3$ and APOE$e3$ homozygotes) into two subgroups.

In summary, we tested for associations using Spearman partial rank-order correlations in which we report 4 p values: (1) the significance of associations between cognition and $^1$H-MRS metabolite ratios; (2) whether adding age to this model is significant; (3) whether adding APOE to this model is significant; and (4) whether adding age and APOE to this model is significant.

RESULTS

Subjects

Characteristics of subjects are described in Table 1. Subjects with Fazekas III and high Hachinski scores (≥7) were excluded in this study in order to reduce and isolate the effect of vascular dementia. There was no significant difference between aMCI ($N = 11$; age: $79 \pm 6.5$, 69–88; 2 female and 9 male; education years: $14 \pm 2.9$, 9–16) and CN ($N = 16$; age: $74 \pm 5.5$, 66–83; 4 female and 12 male; education years: $15 \pm 1.0$, 12–16) in age ($p = 0.056$), gender ($p = 0.675$), and education ($p = 0.342$) by Mann–Whitney U test. Significantly lower cognitive performances in the aMCI (MMSE: $25.7 \pm 3.5$, 20–30; MoCA: $21.0 \pm 3.6$, 14–26; Hachinski: $3.64 \pm 2.42$, 0–6; ADAS-cog: $10.2 \pm 6.27$, 2–23) compared with the CN (MMSE: $28.8 \pm 1.7$, 24–30; MoCA: $26.9 \pm 1.5$, 24–30; Hachinski: $1.81 \pm 1.27$, 0–4; ADAS-cog: $5.5 \pm 2.98$, 1–14) were observed (all $p$ values <0.05).
Table 1  Demographic data and patient characteristics.

|                           | CN n = 16 | aMCI n = 11 | p      | Z/χ² |
|---------------------------|-----------|-------------|--------|------|
| No. female (%)            | 4 (25)    | 2 (18.2)    | 0.675  | 0.175|
| Age, y                    | 74 (66–83)| 79 (69–88)  | 0.056  | −1.929|
| Education, y              | 15 (12–16)| 14 (9–16)   | 0.342  | 0.119|
| No. APOE ε2 carriers (%)  | 1 (6.3)   | 2 (18.2)    |        |      |
| No. APOE ε3 homozygotes (%)| 12 (75)  | 7 (63.6)    | 0.620  | 0.956|
| No. APOE ε4 carriers (%)  | 3 (18.8)  | 2 (18.2)    |        |      |
| No. FazekasII (%)         | 3 (18.8)  | 3 (27.3)    | 0.601  | 0.274|
| MMSE                      | 28.8 (24–30)| 25.7 (20–30)| **0.013** | −2.520|
| MoCA                      | 26.9 (24–30)| 21.0 (14–26)| **0.000** | −4.039|
| ADL                       | 20.3 (20–23)| 22.8 (20–42)| 0.162  | −1.862|
| Hachinski                 | 1.8 (0–4) | 3.6 (0–6)   | **0.026** | −2.257|
| HAMD                      | 2.5 (0–19) | 1.9 (0–7)   | 0.645  | −0.525|
| CDR                       | 0.0 (0.0–0.0)| 0.5 (0.5–0.5)| **0.001** | 11.221|
| ADAS-cog                  | 5.5 (1–14) | 10.2 (2–23) | **0.023** | −2.278|
| Wechsler                  | 32.0 (20–52) | 25.0 (8–57) | 0.099  | −1.680|
| Digit span forward        | 7.8 (6–9)  | 6.9 (4–10)  | 0.134  | −1.540|
| Digit span backward       | 5.1 (3–8)  | 4.2 (2–7)   | 0.162  | −1.442|

Notes.
CN, cognitively normal control; aMCI, amnestic Mild Cognitive Impairment; MMSE, Mini Mental State Examination; MoCA, Montreal cognitive assessment; HAMD, Hamilton Depression Scale; CDR, Clinical Dementia Rating; ADL, Activities of daily living; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive subscale.
* aMCI is significantly different from CN at p < 0.05.
Median (interquartile range) was reported for continuous variables.

1H-MRS metabolite ratios
The characteristics of 1H-MRS metabolite ratios of bilateral hippocampi, including NAA/Cr, mI/Cr and mI/NAA, are described in Table 2. We treated 1H-MRS metabolite ratio as a continuous variable in all analysis. Increased mI/Cr in right hippocampus of aMCI subjects compared with CN was found by Mann–Whitney U test (p = 0.050) (Fig. 2). However, no significant difference in NAA/Cr in bilateral hippocampi and mI/Cr in left hippocampus was found (all p values > 0.05).

Correlation between 1H-MRS metabolite ratios and cognitive function
The correlations between 1H-MRS metabolite ratios, age and cognition scores were measured by Spearman partial rank-order correlations as described in Table 3. Only mI/Cr in right hippocampus was enrolled in the association analysis since it was the only metabolite ratio appeared significant difference between groups. The same principal was applied to cognitive rating scales, as only five of them are shown in Table 3. Age is a major factor of cognition decline and AD neuropathology and therefore was also included in this analysis.

Higher mI/Cr in right hippocampus was associated with worse overall cognitive performance, including MMSE, MoCA, Hachinski, CDR and ADAS-cog. However, only
Figure 2 The MRS result from bilateral hippocampus. The representative example MRS resulting from the left hippocampus of the aMCI and CN subject is respectively shown in (A) and (B), and the group statistical characteristics are shown in (C). The MRS resulting from right hippocampus are showed in (D–F). All spectra are scaled to the height of the reference peak Cr, shown with a dotted line. Spectra from the right hippocampus demonstrates the increased ml/Cr in a patient with aMCI (D) compared with CN (E) at $p = 0.05$ (F).

Table 2 MRS metabolite ratios in median (interquartile range) in aMCI group compared with CN.

|        | CN $n = 16$ | aMCI $n = 11$ | $p$  | $Z$  |
|--------|-------------|---------------|------|------|
| NAA/Cr R | 2.38 (1.68–3.92) | 2.60 (2.00–3.43) | 0.134 | −1.530 |
| NAA/Cr L | 2.06 (0.13–3.26) | 2.22 (1.40–3.37) | 0.680 | −0.444 |
| ml/Cr R | 0.64 (0.41–0.78) | 0.72 (0.39–0.92) | **0.050** | −1.977 |
| ml/Cr L | 0.75 (0.36–1.37) | 0.79 (0.47–1.48) | 0.753 | −0.321 |
| ml/NAA R | 0.28 (0.16–0.40) | 0.28 (0.12–0.46) | 0.942 | −0.099 |
| ml/NAA L | 0.95 (0.13–10.31) | 0.35 (0.24–0.57) | 0.753 | −0.321 |

Notes.
Median (interquartile range) was reported for continuous variables. $p$ values for group comparison are from Mann-Whitney Tests.
R, right hippocampus; L, left hippocampus; NAA, N-acetyl aspartate; ml, myo-inositol; Cr, creatine.
* is significantly different between groups at $p \leq 0.05$.

the correlation between ml/Cr and MoCA is significant ($r_s = −0.403, p = 0.025$). Age was significantly associated with MMSE ($r_s = −0.508, p = 0.007$), MoCA ($r_s = −0.407, p = 0.035$) and ADAS-cog ($r_s = 0.469, p = 0.014$). However, no correlation between age and ml/Cr in right hippocampus was found ($p = 0.678$).
Table 3 The statistically significant correlations between clinical rating scales, age and the mI/Cr ratios from the right hippocampus.

|       | MMSE | MoCA | Hachinski | ADAS-cog | CDR   | Age       |
|-------|------|------|-----------|----------|-------|-----------|
| Sig   | r_s  | Sig  | r_s       | Sig      | r_s   | Sig       | r_s       |
| mI/Cr | 0.953| −0.012| 0.025*    | 0.719    | −0.073| 0.522     | 0.129     |
| Age   | 0.007*| −0.508| 0.035      | 0.081    | 0.342 | 0.014      | 0.469     |

Notes. Only statistically different clinical rating scales between groups were enrolled in this correlations analysis.

MMSE, Mini Mental State Examination; MoCA, Montreal cognitive assessment; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive subscale; CDR, Clinical Dementia Rating; R, right hippocampus; mI, myo-inositol; Cr, creatine.

* is significantly different between groups at p ≤ 0.05.

Table 4 The effects of APOE and age on the association between mI/Cr ratios and clinical rating scale (the scores of MoCA).

|       | Sig   | r_s  |
|-------|-------|------|
| mI/Cr | 0.025*| −0.431|
| (controlling for age) | 0.073 | −0.338 |
| (group by APOE genotype) | non-ε4 carrier | 0.152 | −0.316 |
| | ε4 carrier | 0.219 | −0.667 |
| (group by APOE genotype and controlling for age) | non-ε4 carrier | 0.115 | −0.354 |
| | ε4 carrier | 0.138 | −0.862 |

Notes. MoCA, Montreal cognitive assessment; R, right hippocampus; mI, myo-inositol; Cr, creatine.

* is significantly different between groups at p ≤ 0.05.

Effect of APOEε4 allele and age on the association between cognitive function and 1H-MRS metabolite ratios

Since there was correlation between MoCA and mI/Cr, we further analyze the effect of APOE and age on this association by partial correlation. No correlation was found between cognition and mI/Cr in right hippocampus after controlling for age ($r_s = −0.358$, $p = 0.073$) as described in Table 4, indicating that there was an interaction with age for the association between cognitive function and 1H-MRS metabolite ratios.

The effect of APOE status was measured by separating the subjects into APOE genotype subgroups, the APOEε4 carriers ($n = 5$, allele ε3ε4 and ε4ε4) and APOEε4 non-carriers ($n = 22$, allele ε2ε3 and ε3ε3). We did not find any differences in mI/Cr (Fig. 3A) and cognition scores (Fig. 3B) between the 2 groups. No correlation was found between cognition and mI/Cr in right hippocampus in both APOEε4 carriers ($r_s = −0.667$, $p = 0.219$) and APOEε4 non-carriers ($r_s = −0.316$, $p = 0.152$) (Fig. 4). Furthermore, there was no correlation between cognitive function and 1H-MRS metabolite ratios in both APOEε4 carriers ($r_s = −0.862$, $p = 0.138$) and APOEε4 non-carriers ($r_s = −0.354$, $p = 0.115$) after controlling for age, indicating that the APOE status and age might influence the correlation between cognition and 1H-MRS metabolite ratios as shown in Table 4.
DISCUSSION

Findings of this study indicated that the glial activity marker ml/Cr from the right hippocampus increased in patients with aMCI compared with those from normal elderly. Furthermore, there is an association between higher ml/Cr in right hippocampus and worse cognitive function in non-demented older adults and this relationship could be modified by APOE status and age.

The neurofibrillary tangles pathology of AD follow a typical progression from limbic to neocortical regions as AD advances (Braak & Braak, 1991). A similar temporal course of changes in these metabolites is seen with aMCI, a prodromal stage of AD (Knopman, 2013; Petersen et al., 2009). Therefore, it is reasonable that we selected to measure metabolites in bilateral hippocampus known as the earliest involved limbic region in aMCI patients.
Our findings are consistent with prior studies showing that aMCI patients have elevated myo-inositol levels in the right hippocampus, which is associated with glial proliferation (Miller et al., 1993). We did not find the changes in NAA/Cr from the hippocampus in our subject sample, which supports the hypothesis that the elevation of mI/Cr ratio precedes the decrease in NAA/Cr ratio during the progression of aMCI, mild AD and AD (Kantarci et al., 2000). This finding is consistent with a previous 1H-MRS study in aMCI (Kantarci et al., 2000; Kantarci et al., 2007; Zhang et al., 2009), mild AD (Huang et al., 2001) and in presymptomatic carriers of the familial AD mutations (Godbolt et al., 2006) which suggested that mI/Cr elevation is an early event in the progression of AD pathology.

In an imaging–autopsy correlation study, the antemortem mI/Cr levels correlated with the density of neuritic plaques in subjects at autopsy (Kantarci et al., 2008). If mI/Cr is a marker associated with the amyloid pathology of AD, then the higher mI/Cr will be expected to relate with the worse cognitive performance. In our study, mI/Cr ratios negatively correlated with the general cognition status (MoCA scores), which is in consistent with former studies (Jessen et al., 2000; Kantarci et al., 2002). Associations were present in regions where there was significant amyloid deposition, such as hippocampus. Based on this, we might expect to find an association between higher mI/Cr and worse cognitive performance in bilateral hippocampus. However, we only found the mI/Cr changed in right hippocampus, not in the left. There were published researches indicating that the rightward asymmetry of hippocampal connectivity observed in elderly controls was diminished in AD patients (Wang et al., 2006). Based on this potentially asymmetric hippocampus function, it is reasonable that the metabolites might change in different rate or extent between bilateral hippocampus. However, due to the small sample size limitation in our study, there is not sufficient evidence to support the hippocampus involved asymmetrically. The absence of this expected correlation requires further large sample and longitudinal investigation.

The association between the brain metabolites and cognition in old adults appear to be multifactorial, such as genotype and age. In humans, there are three common alleles of the APOE gene, numbered 2, 3 and 4. In line with prior research (Munoz & Feldman, 2000), APOEε4 is disproportionately represented in our patient sample (16.6% of the patient sample was ε4+ compared to 11.5% of the control sample). Increasing researches showed that the APOEε4 allele is associated with a greatly increased risk of AD (Strittmatter et al., 1993). However, the function of the APOE protein, and its relationship with metabolites in the brain remains mostly unknown. Although one study showed that myo-inositol were significantly increased in APOEε4 carriers in a healthy aging normal population (Gomar et al., 2014), there is still no evidence in aMCI carriers. In our cohort, the presence of an APOEε4 allele influences the relationship between mI and cognitive function in non-demented people. We dichotomized the non-demented subjects into APOEε4 carriers and non-carriers groups, and did not find any differences in mI/Cr and cognition scores between the 2 groups. Within each group, there was no correlation between the mI/Cr ratio and MoCA scores, indicating APOE as the mediator modified this relationship, since there was correlation between metabolites and cognition before separating the
genotyping. Further, we note that the mI/Cr trends to decrease and the cognition scores trends to increase with the presence of an APOEε4 allele. There was relatively little cognitive disturbance in non-demented APOEε4 carriers in this small cohort, suggesting the influence of additional mediators such as potential compensatory progress in aMCI, which need further confirmation in the future (Kantarci et al., 2012).

Moreover, age is the main factors affecting cognitive function. But the age effects on 1H-MRS metabolites have been inconsistently described, have been small effect, or have been dependent on metabolite and voxel placement (Haga et al., 2009). In our sample, we found the negative correlation between age and MoCA, indicating cognition decline in old people, which is in line with other studies (Ashworth et al., 2014; Yu et al., 2014). While using controlling age as the covariates, the correlation between mI/Cr ratio and MoCA scores disappeared. Based on this result, age is another main factor affecting the correlation between metabolites and cognitive function. Further large cohort is required to confirm the age effect on the association.

Several other technique points about our study may be worth considering. One potential concern is the metabolites from hippocampus measuring by the 2D 1H-MRS. Compared with single voxel MRS, the surrounding tissue (i.e., fat, bone, air and cerebral spinal fluid) can be relatively easily avoided by selecting the usable voxels from the multi voxels in the field of volume, which making the metabolites from the relative pure hippocampus tissue. In addition, 2D MRS had more sampling points, and we could get more data. The mean value was more accurate and persuasive. Secondly, the metabolite measurements in this study were obtained from right and left hippocampus, respectively, which improved the quality of the shimming in the field of volume for each of the hippocampus. Thirdly, we controlled the data quality from multi-voxel chemical shift imaging 1H-MRS following several technical aspects: (1) using short echo time (TE = 32 ms) in 1H-MRS acquisitions was critical to this study, because mI has a relatively short transverse relaxation time and can be quantified only at short echo times; (2) Because the various metabolites in the tissue of interest process are at different frequencies, as a result, the selected volume will be different for the different metabolites, i.e., chemical shift displacement. Therefore, the chemical shift distance were considered in to the localization process by double-checked the chemical shift voxels of NAA and mI, respectively.

A limitation of our study is the insufficient follow-up on the cohort and the small sample size we scanned during the last 2 years. Overall, our in vivo 1H-MRS data are consistent with the biochemical changes underlying the known pathology in each of the related studies. Moreover, due to the small sample size limitation, we did not separate the cohort into aMCI subtype with different cognitive domain impairment. Amnestic MCI has higher risk at AD progression, and it is expected to have higher mI/Cr ratio and stronger correlation with APOE status.

In summary, we found mI/Cr ratios from right hippocampus increased in aMCI, suggesting glial proliferation changes could be a more specific predictor of general cognitive function in aMCI patients. Furthermore, we demonstrated that the APOE status and age modified the associations between mI/Cr from right hippocampus measured by
2D $^1$H-MRS and cognitive function in non-demented subjects. The findings of this study are of significance in further understanding the influence of changes of brain metabolites on cognitive functions, where age and APOE genotype should be taken into consideration.

**ACKNOWLEDGEMENT**

The statistical analysis was supported by Biyun Xu, a statistician belonging to the Affiliated Drum Tower Hospital of Nanjing University Medical School.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**

This work was supported by the National Science Foundation of China, (2014-2016, 81300925, BZ), the Provincial Natural Science Foundation of Jiangsu (2014-2016, BK20131085, BZ), and Jiangsu Province Medical Key talent people and “the 12th five years plan for China development” (2011-2-16, RC2011013, BZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Grant Disclosures**

The following grant information was disclosed by the authors:
National Science Foundation of China: 2014-2016, 81300925.
Provincial Natural Science Foundation of Jiangsu: 2014-2016, BK20131085.
Jiangsu Province Medical Key.
12th five years plan for China development: 2011-2-16, RC2011013.

**Competing Interests**

The authors declare there are no competing interests.

**Author Contributions**

- Zhenyu Yin conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables.
- Wenbo Wu performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables.
- Renyuan Liu performed the experiments, analyzed the data.
- Xue Liang performed the experiments, analyzed the data, prepared figures and/or tables.
- Tingting Yu, Xiaoling Chen, Jie Feng, Aibin Guo, Yu Xie, Haiyan Yang and Mingmin Huang contributed reagents/materials/analysis tools.
- Chuanshuai Tian performed the experiments.
- Bing Zhang and Yun Xu conceived and designed the experiments, reviewed drafts of the paper.
Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The study has been approved by the Medical Research Ethics Committee of Nanjing Drum Tower Hospital, Nanjing, China—#NJMU20113343.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.1202#supplemental-information.

REFERENCES

Ashworth B, Dilks I, Hutchinson K, Hayes S, Moore M, Orozoco A, DeRoche K, Julian A, Barnett O. 2014. A-67A pilot study of age and education norms for the montreal cognitive assessment. Archives of Clinical Neuropsychology 29:527–528 DOI 10.1093/arclin/acu038.67.

Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 82:239–259 DOI 10.1007/BF00308809.

Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L, Fox NC, Rossor MN. 2006. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66:718–722 DOI 10.1212/01.wnl.0000201237.05869.df.

Gomar JJ, Gordon ML, Dickinson D, Kingsley PB, Ulug AM, Keelhisen L, Huet S, Buthorn JJ, Koppel J, Christen E, Conejero-Goldberg C, Davies P, Goldberg TE. 2014. APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain. Biological Psychiatry 75:686–692 DOI 10.1016/j.biopsych.2013.05.022.

Graff-Radford J, Kantarci K. 2013. Magnetic resonance spectroscopy in Alzheimer’s disease. Neuropsychiatric Disease and Treatment 9:687–696 DOI 10.2147/NDT.S35440.

Haga KK, Khor YP, Farrall A, Wardlaw JM. 2009. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiology of Aging 30:353–363 DOI 10.1016/j.neurobiolaging.2007.07.005.

Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB. 2001. Brain metabolite concentration and dementia severity in Alzheimer’s disease: a (1)H-MRS study. Neurology 57:626–632 DOI 10.1212/01.WNL.57.4.626.

Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, Lamerichs R, Heun R, Schild HH. 2000. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55:684–688 DOI 10.1212/01.WNL.55.5.684.

Kantarci K. 2007. 1H magnetic resonance spectroscopy in dementia. British Journal of Radiology 80(Spec No 2):S146–S152 DOI 10.1259/bjr/60346217.

Kantarci K, Jack Jr CR, Xu YC, Campeau NG, O’Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC. 2000. Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: a 1H-MRS study. Neurology 55:210–217 DOI 10.1212/01.WNL.55.2.210.

Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack Jr CR. 2008. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 248:210–220 DOI 10.1148/radiol.2481071590.
Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, Ivnik RJ, Preboske GM, Roberts R, Geda YE, Boeve BF, Knopman DS, Petersen RC, Jack Jr CR. 2012. APOE modifies the association between Abeta load and cognition in cognitively normal older adults. *Neurology* 78:232–240 DOI 10.1212/WNL.0b013e31824365ab.

Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, Tangalos EG, Jack Jr CR. 2002. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer’s disease. *Journal of the International Neuropsychological Society* 8:934–942 DOI 10.1017/S1355617702870084.

Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, Reyes D, Shiung M, O’Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Jack Jr CR. 2007. Longitudinal 1H-MRS changes in mild cognitive impairment and Alzheimer’s disease. *Neurobiology of Aging* 28:1330–1339 DOI 10.1016/j.neurobiolaging.2006.06.018.

Knopman DS. 2013. Alzheimer disease biomarkers and insights into mild cognitive impairment. *Neurology* 80:978–980 DOI 10.1212/WNL.0b013e31828728ac.

Kozauer NA, Mielke MM, Chan GK, Rebok GW, Lyketsos CG. 2008. Apolipoprotein E genotype and lifetime cognitive decline. *International Psychogeriatrics* 20:109–123 DOI 10.1017/S104161020700587X.

Mastaglia FL, Rojana-udomsart A, James I, Needham M, Day TJ, Kiers L, Corbett JA, Saunders AM, Lutz MW, Roses AD. 2013. Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. *Neuromuscular Disorders* 23:969–974 DOI 10.1016/j.nmd.2013.09.008.

Michaelson DM. 2014. APOE epsilon4: the most prevalent yet understudied risk factor for Alzheimer’s disease. *Alzheimers and Dementia* 10:861–868 DOI 10.1016/j.jalz.2014.06.015.

Miller BL, Moats RA, Shonk T, Ernst T, W oolley S, Ross BD. 1993. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. *Radiology* 187:433–437 DOI 10.1148/radiology.187.2.8475286.

Munoz DG, Feldman H. 2000. Causes of Alzheimer’s disease. *Canadian Medical Association Journal* 162:65–72.

Murray ME, Przybelski SA, Lesnicky TG, Liesinger AM, Spychalla A, Zhang B, Gunter JL, Parisi JE, Boeve BF, Knopman DS, Petersen RC, Jack Jr CR, Dickson DW, Kantarci K. 2014. Early Alzheimer’s disease neuropathology detected by proton MR spectroscopy. *Journal of Neuroscience* 34:16247–16255 DOI 10.1523/JNEUROSCI.2027-14.2014.

Negash S, Greenwood PM, Sunderland T, Parasuraman R, Geda YE, Knopman DS, Boeve BF, Ivnik RJ, Petersen RC, Smith GE. 2009. The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80. *Neuropsychology* 23:81–89 DOI 10.1037/a0014014.

Petersen RC. 2000. Mild cognitive impairment: transition between aging and Alzheimer’s disease. *Neurologia* 15:93–101.

Petersen RC. 2004. Mild cognitive impairment as a diagnostic entity. *Journal of Internal Medicine* 256:183–194 DOI 10.1111/j.1365-2969.2004.01388.x.

Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack Jr CR. 2009. Mild cognitive impairment: ten years later. *Archives of Neurology* 66:1447–1455 DOI 10.1001/archneur.2009.266.

Rose SE, De Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, Semple J, Doddrell DM. 1999. A 1H-MRS study of probable Alzheimer’s disease and normal aging: implications for longitudinal monitoring of dementia progression. *Magnetic Resonance Imaging* 17:291–299 DOI 10.1016/S0730-725X(98)00168-4.
Shen J, Zhang L, Tian X, Liu J, Ge X, Zhang X. 2009. Use of short echo time two-dimensional 1H-magnetic resonance spectroscopy in temporal lobe epilepsy with negative magnetic resonance imaging findings. *Journal of International Medical Research* **37**:1211–1219 DOI 10.1177/147323000903700428.

Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America* **90**:1977–1981 DOI 10.1073/pnas.90.5.1977.

Tumati S, Martens S, Aleman A. 2013. Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis. *Neuroscience and Biobehavioral Reviews* **37**:2571–2586 DOI 10.1016/j.neubiorev.2013.08.004.

Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, Wu T, Jiang T, Li K. 2006. Changes in hippocampal connectivity in the early stages of Alzheimer’s disease: evidence from resting state fMRI. *NeuroImage* **31**:496–504 DOI 10.1016/j.neuroimage.2005.12.033.

Weis J, Bruvold M, Ortiz-Nieto F, Ahlstrom H. 2014. High-resolution echo-planar spectroscopic imaging of the human calf. *PLoS ONE* **9**:e87533 DOI 10.1371/journal.pone.0087533.

Yu J, Su T, Zhou T, He Y, Lu J, Li J, He R. 2014. Uric formaldehyde levels are negatively correlated with cognitive abilities in healthy older adults. *Neuroscience Bulletin* **30**:172–184 DOI 10.1007/s12264-013-1416-x.

Zhang B, Li M, Sun ZZ, Zhu B, Yuan L, Wang Y, Xu Y. 2009. Evaluation of functional MRI markers in mild cognitive impairment. *Journal of Clinical Neuroscience* **16**:635–641 DOI 10.1016/j.jocn.2008.07.080.

Yin et al. (2015), *PeerJ* DOI 10.7717/peerj.1202